A future biomarker may help match melanoma patients with the best therapy for them

Immune checkpoint blockade medications have revolutionized cancer treatment, giving patients and providers new hope to control and sometimes cure metastatic cancer. However, predicting which patients will benefit from this expensive and sometimes toxic, but potentially lifesaving, class of medications has been a challenge.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup